GLP-1 and GIP Drugs Reduce Heart Attack and Stroke Risk Beyond Weight Loss Alone | Research

The takeaway

Incretin agonists including GLP-1 and dual GLP-1/GIP drugs reduce body weight by 10-20% and significantly lower major cardiovascular events in both diabetic and non-diabetic patients.

10-20% weight loss + CV protection
Incretin drugs provide dual benefits: substantial weight loss AND independent cardiovascular risk reduction

What the researchers found

Incretin agonists reduce body weight by 10-20% and significantly lower major adverse cardiovascular events (cardiovascular death, nonfatal MI, stroke) in patients with and without diabetes, with benefits extending beyond glycemic control.

Why it matters

Obesity-related cardiovascular disease is the leading cause of death worldwide. The dual metabolic and cardiovascular benefits of incretin drugs position them as transformative treatments that address both root causes.

How the study worked

Narrative review of mechanistic pathways linking obesity to cardiovascular disease and clinical trial evidence for pharmacologic therapies including incretin agonists.

What this study cannot tell us

Narrative review without new data. Long-term cardiovascular outcomes beyond trial durations are unknown. Cost and access remain barriers. Not all patients respond equally.

How to read the evidence

Narrative review synthesizing large cardiovascular outcome trials (SELECT, STEP-HFpEF, SURMOUNT, etc.). Evidence is robust from multiple RCTs.

When this study was published

Published in 2025, reflecting the latest cardiovascular outcome data for incretin-based therapies.

The bigger picture

These drugs mark a paradigm shift from treating obesity and cardiovascular disease as separate conditions to addressing them together with a single therapeutic approach.

Questions still open

How long do the cardiovascular benefits persist after stopping GLP-1 drugs?
Will next-generation triple agonists (GLP-1/GIP/glucagon) provide even greater cardiovascular protection?
Should all obese patients with cardiovascular risk receive incretin therapy regardless of diabetes status?

Common questions

Can GLP-1 drugs prevent heart attacks?

Clinical trials show GLP-1 drugs significantly reduce the risk of heart attacks, strokes, and cardiovascular death. This benefit occurs in both diabetic and non-diabetic patients and appears to go beyond what weight loss alone would explain.

Is tirzepatide better than semaglutide for the heart?

Tirzepatide produces greater weight loss than GLP-1-only drugs, but head-to-head cardiovascular outcome data comparing the two are still emerging. Both classes show significant cardiovascular benefits.

Read the original research

Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions.

Current atherosclerosis reports, 28(1), 21

View on PubMed ↗Publisher’s paper ↗

Citation

De Oliveira-Gomes, Diana; de Majo, Alfonso Martinez; Ardila-Delgado, Angie; Inglis, Sara S; Mandras, Stacy A; Loro-Ferrer, Juan F; daSilva-deAbreu, Adrian. (2026). Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions.. Current atherosclerosis reports, 28(1), 21. https://doi.org/10.1007/s11883-026-01395-2